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Abstract
Objective: To evaluate the impact of adalimumab on health-related quality of life (HRQOL) for patients with moderate to
severe plaque psoriasis.
Background: Psoriasis is a chronic, inflammatory, immune-mediated disease that has a significant impact on patients' HRQOL.
Adalimumab is a fully human monoclonal antibody that blocks tumor necrosis factor, a pro-inflammatory cytokine, and is
effective and well-tolerated for patients with moderate to severe psoriasis.
Methods: Data were obtained for a secondary analysis of patients in a randomized, controlled Phase III trial evaluating the effect
of adalimumab in patients with psoriasis (N = 1,205). Patients with moderate to severe psoriasis were randomized in a 2:1 ratio
to adalimumab 80 mg (two 40 mg injections administered subcutaneously at baseline followed by one 40 mg injection every
other week from Week 1 to Week 15) or placebo. Short Form-36 (SF-36) Health Survey scores of psoriasis patients were used
to assess HRQOL and were compared with United States (US) population norms at baseline and Week 16.
Results: Baseline Physical Component Summary (PCS) scores for the placebo and adalimumab groups were similar to the
general US population. Baseline mean Mental Component Summary (MCS) scores were significantly lower for the adalimumab
and placebo groups compared with the general population (47.4, 47.7, and 50.8 points, respectively; p < 0.0001). PCS scores at
Week 16 for patients receiving adalimumab had improved and were significantly greater than scores for the general US
population (52.7 vs 48.9; p < 0.001). Compared with the general US population, MCS scores at Week 16 were similar for
patients receiving adalimumab (51.2 vs 50.8; p = 1.000) and lower for patients receiving placebo (50.8 vs 48.7; p < 0.0001).
Conclusion: Psoriasis has a broad impact on patient functioning and well-being. Improvement in skin lesions and joint symptoms
associated with adalimumab treatment was accompanied by improvements in HRQOL to levels that were similar to or greater
than those of the general US population.
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Introduction
Psoriasis is a chronic, inflammatory, immune-mediated
disease that has significant impact on patients' health-
related quality of life (HRQOL) [1-7]. Psoriasis symp-
tomatology, including pain and itching, combined with
concerns about the appearance of one's skin can substan-
tially affect a patient's psychological well-being and can
result in emotional distress, a sense of stigmatization,
worry, and embarrassment. Deficits in social and sexual
functioning, as well as social, recreational, and work activ-
ity restrictions have all been reported in patients with pso-
riasis. A survey of National Psoriasis Foundation members
with severe psoriasis found that the disease negatively
impacted the HRQOL of nearly 80% of respondents [8].
HRQOL outcomes provide greater insight into the impact
of psoriasis on patient functioning and well-being than do
clinical measures, such as the percentage of body surface
area (BSA) affected by psoriasis [9].
To more fully understand the impact that psoriasis and its
treatments have on a patient's functioning and well-being,
it is important that clinical trials of new psoriasis treat-
ments assess patient HRQOL. Successful treatment of
moderate to severe psoriasis with TNF antagonists
improves physical function, as well as social and psycho-
logical aspects of psoriasis [10-17]. Adalimumab, a fully
human monoclonal antibody that blocks TNF, is effective
and well-tolerated for patients with moderate to severe
psoriasis [16-19].
In a 16-week, Phase III, randomized, double-blind, pla-
cebo-controlled trial, adalimumab improved HRQOL out-
comes in patients with psoriasis, as measured with both the
Dermatology Life Quality Index (DLQI) and the Mental
and Physical Component Summary scores of the Short
Form-36 Health Survey (SF-36) [16,17]. However, the
meaning associated with the magnitude of change in
HRQOL scores is not well-characterized. There is currently
little guidance for interpreting changes in HRQOL scores.
Most often information on minimum clinically important
differences for HRQOL scores are determined by anchor-
based and distribution-based methods [20,21]. Relevant
anchors may be clinical endpoints, global clinician or
patient ratings of improvement in symptom or health sta-
tus, or other measures. It is important for clinicians to
understand that changes in HRQOL scores also reflect
changes in clinical status or function and may therefore
impact treatment decisions. Criterion-based interpretation,
which uses the relationship of these scores to external vari-
ables or population norms to assign meaning, is one
approach to relating the importance of scores in terms that
are more easily understood by clinicians and patients [2].
The objective of this secondary analysis was to evaluate
the effect of adalimumab on initial improvement in
HRQOL for patients with psoriasis compared with the
general population of the United States (US). The norm-
based approach compared mean HRQOL scores in a tar-
get patient group (in this case psoriasis) to age-, sex-, and
race-matched mean HRQOL scores from members of the
general US population. This information then allowed the
quantification of HRQOL burden before and after treat-
ment, and also demonstrated improvements in health
outcomes based on comparisons between the clinical
study patients and the general US population, adjusted for
age, sex, and race.
Patients and methods
Patient population
Moderate to severe psoriasis patient sample
The data for this secondary analysis came from the Rand-
omized Controlled EValuation of Adalimumab Every
Other Week Dosing in Moderate to Severe Psoriasis TriAL
(REVEAL) study, a 52-week, Phase III clinical trial in adult
patients with moderate to severe chronic plaque psoriasis
[23]. Patients were randomized in a 1:2 ratio to receive
subcutaneous injections of placebo only or adalimumab
80 mg at Week 0 followed by 40 mg every other week
from Week 1 to Week 15 during the initial 16-week, dou-
ble-blind treatment period. Following the initial treat-
ment period, all patients who achieved at least 75%
improvement in Psoriasis Area and Severity Index (PASI)
scores (PASI 75 response) received adalimumab 40 mg
every other week. Because few placebo-treated patients
(17.3%; n = 57) were observed after Week 16 and all
patients received adalimumab after Week 16, the analyses
reported here are based only on data collected at baseline
and at Week 16.
To be eligible for the study, patients were required to meet
the following disease severity indices at the baseline visit:
moderate to severe plaque psoriasis defined as ≥ 10% BSA
involvement, a PASI score of ≥ 12 and a Physician's Global
Assessment of at least moderate disease. The REVEAL
study was conducted in accordance with the principles of
the Declaration of Helsinki, and all study sites received
approval from independent ethics committees. All
patients provided written, informed consent before any
study-related procedures were performed.
US general population samples
General population normative data came from two
sources: the 1998 National Survey of Functional Health
Status (NSFHS) and the 2002 Medical Expenditures Panel
Survey (MEPS). The NSFHS is a representative sample (N
= 1,982) of the non-institutionalized adult population in
the United States [24,25] and was included to allow nor-
mative comparisons for SF-36 Health Survey (Version 1)
scale scores between the general US population and
REVEAL study patients. The MEPS is a nationally repre-Health and Quality of Life Outcomes 2008, 6:75 http://www.hqlo.com/content/6/1/75
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sentative, cross-sectional sample of the non-institutional-
ized US civilian population (N = 23,517) [26]. To use
more recent data, MEPS health status data were employed.
This survey also enabled similar comparisons for the SF-
36 Physical Component Summary (PCS) and Mental
Component Summary (MCS) scores and allowed adjust-
ment for age, sex, and race in the data analyses.
Instruments used for assessment of health-related quality 
of life
The SF-36 Health Survey (Version 1) is a 36-item general
health status instrument often used in clinical trials and
health services research. The SF-36 consists of 8 scales:
Physical Function, Role Limitations-Physical, Vitality,
General Health Perceptions, Bodily Pain, Social Function,
Role Limitations-Emotional, and Mental Health [7]. Two
overall summary scores (PCS and MCS) are obtained from
the SF-36. Norm-based scoring algorithms were used for
the scales and for the PCS and MCS scores, which are
normed to a mean of 50 and standard deviation of 10,
with greater scores indicating better health. Change scores
of 2 to 3 points for the individual normed scales, equiva-
lent to a 0.2 to 0.3 effect size, can be used as guidelines to
interpret clinically meaningful differences; differences of
2 to 3 points for the summary scores are considered the
minimum important difference in the general US popula-
tion [7]. There is extensive evidence demonstrating the
reliability and validity of the SF-36 [4] in general popula-
tions. The SF-36 has also demonstrated acceptable relia-
bility, validity, and responsiveness to change in
dermatology populations [9]. The SF-36 was included in
both the REVEAL and NSFHS studies.
The Short Form-12 Health Survey (SF-12) (Version 1),
which was used in the MEPS survey included in this anal-
ysis, contains 12 items from the SF-36 Health Survey, with
1 or 2 items measuring each of the 8 concepts included in
the SF-36. SF-12 summary scores (PCS and MCS) are
normed with a general population mean of 50 and stand-
ard deviation of 10, and greater scores reflect better health
status. The psychometric properties of the SF-12 are well-
established in various diseases [25]. Instrument develop-
ers have demonstrated that SF-12 and SF-36 summary
scores are comparable [25].
Statistical analyses
Descriptive statistics
Descriptive statistics were reported for demographic and
clinical characteristics of the REVEAL sample. Means and
standard deviations were used to describe continuous var-
iables, whereas frequency distributions were used to
describe categorical variables. Student t-tests were used to
compare independent groups and chi-square tests were
used to compare score differences between groups. The
sample for the current analyses was comparable to that of
the HRQOL analysis for the REVEAL trial [30] and
included all randomized patients who had completed the
baseline primary HRQOL assessment (based on the DLQI
and SF-36) and at least one follow-up assessment within
16 weeks of study entry.
Assessing the burden of psoriasis on health-related quality of life in 
psoriasis
SF-36 scale score norms were derived from NSFHS data
collected in 1998 [24] for men and women 45 to 50 years
of age (similar to the REVEAL sample) and were compared
with baseline SF-36 scale scores for each of the REVEAL
treatment groups (adalimumab and placebo) before treat-
ment initiation. PCS and MCS scores for each of the
REVEAL treatment groups were also compared with US
normative data derived from the more recent MEPS sur-
vey.
Assessing the impact of treatment on health-related quality of life in 
psoriasis
SF-36 scale score norms for men and women 45 to 54
years of age from the NSFHS were compared with SF-36
scale scores by treatment group at Week 16 [24]. To com-
pare PCS and MCS scores from the REVEAL study sample
to the MEPS data sample (US general population norms),
two analyses were performed. First, separate least squares
regression models for PCS and MCS scores from the
REVEAL study were compared with summary scores from
MEPS adjusted for age, sex, and race. The F-test was used
to test for the group factor and the Bonferroni method was
used to adjust for multiple comparisons. Second, a
matched-case analysis was performed. For each patient in
the REVEAL study, 5 age-, sex-, and race-matched controls
were randomly chosen from the MEPS data, except in
cases for which fewer than 5 controls were available. Stu-
dent t-tests for independent groups were used to assess
mean score differences between groups. PCS and MCS
scores for the REVEAL study were calculated from the SF-
36, whereas the PCS and MCS scores for the MEPS were
calculated from the SF-12.
Results
Demographics and clinical characteristics
A total of 1,205 patients from the REVEAL study were
included in this analysis: 808 patients received adalimu-
mab and 397 patients received placebo. Baseline demo-
graphic and clinical characteristics were similar between
the two treatment groups and were indicative of moderate
to severe plaque psoriasis (Table 1).
Assessing the burden of psoriasis on health-related quality 
of life
SF-36 summary scores
Based on the 2002 MEPS data, baseline PCS scores for
patients in the REVEAL study were similar to the generalHealth and Quality of Life Outcomes 2008, 6:75 http://www.hqlo.com/content/6/1/75
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US population for those receiving adalimumab (adalimu-
mab mean = 48.9 vs MEPS mean = 48.9; p = 0.2636) and
placebo (placebo mean = 49.1 vs MEPS mean = 48.9; p =
1.000). Mean MCS scores were significantly lower for the
adalimumab and placebo treatment groups compared
with the MEPS sample (47.4, 47.7, and 50.8 points,
respectively; p < 0.0001 for both treatment groups). Simi-
lar findings were observed for the matched-case analysis.
SF-36 scale scores
Table 2 summarizes the baseline SF-36 scale scores for the
REVEAL treatment groups and for the general US popula-
tion based on men and women 45 to 54 years of age in the
NSFHS study. Patients in each REVEAL treatment group
generally had lower baseline SF-36 scale scores compared
with the general US population, with the largest differ-
ences seen in Social Function (-4.05 and -3.96 points) and
Table 1: Baseline characteristics for all eligible patients in the REVEAL study
Treatment Group
Adalimumab (N = 808) Placebo (N = 397) P-value1
Age (yrs), mean ± SD1 44.1 ± 13.2 45.4 ± 13.4 0.1177
Sex, n (% female)1 266 (32.9) 141 (35.5) 0.3996
Race, n (%)2 0.5432
White 738 (91.3) 358 (90.2)
Black 27 (3.3) 20 (5.0)
Asian 21 (2.6) 7 (1.8)
American Indian/Alaska Native 3 (0.4) 1 (0.3)
Other 19 (2.4) 11 (2.8)
Ethnicity, n (%)2 0.3434
Not Hispanic or Latino 754 (93.3) 364 (91.7)
Hispanic or Latino 54 (6.7) 33 (8.3)
Psoriasis history
Duration of psoriasis (yrs), mean ± SD1 18.6 ± 12.0 18.8 ± 12.0 0.7309
Concomitant psoriatic arthritis, (% yes)2 222 (27.5) 113 (28.5) 0.7326
Prior systemic psoriasis therapy, (% yes)2 260 (32.2) 128 (32.2) 1.0000
Psoriasis baseline assessments
Percentage of body surface area affected by psoriasis, mean ± SD2 25.8 ± 15.5 25.6 ± 14.8 0.8796
Psoriasis Area and Severity Index, mean ± SD2 19.0 ± 7.1 18.8 ± 7.1 0.7787
Physician's global assessment score, n (% yes)2 1.0000
Moderate2 416 (51.5) 219 (55.2)
Severe 341 (42.2) 155 (39.0)
Very severe 51 (6.3) 23 (5.8)
1t-Test.
2Fisher exact test or chi-square test.
3P-value for comparison between adalimumab versus placebo.
Table 2: HRQL impact of psoriasis at baseline: study population versus general US population
Adalimumab Mean (SD)1 Placebo Mean (SD)2 General US Population3 Mean (SD)
Physical Functioning 48.6 (10.3) 48.2(10.6) 49.4 (10.0)
Role-Physical 48.2 (11.1) 48.7 (10.8) 50.1 (9.9)
Bodily Pain 47.5 (10.9) 47.4 (10.6) 49.2 (10.2)
General Health 49.5 (9.5) 50.2 (9.5) 49.3 (10.7)
Vitality 49.9 (9.8) 50.3 (10.3) 50.4 (10.5)
Social Functioning 46.0 (11.8) 46.1 (11.7) 50.1 (10.1)
Role-Emotional 47.6 (12.0) 47.4 (12.0) 50.6 (9.5)
Mental Health 47.4 (10.8) 47.9 (11.0) 49.4 (10.7)
1N = 804–808.
2N = 396–397.
3SF-36 values for males and females aged 45 to 54 years from SF-36 manual (1998 population); N = 417.Health and Quality of Life Outcomes 2008, 6:75 http://www.hqlo.com/content/6/1/75
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Role-Emotional (-3.00 and -3.20 points) scores for the
adalimumab and placebo groups, compared with the gen-
eral US population. These observed differences are consid-
ered clinically meaningful, given they exceed the 3.0 point
minimum clinically important difference (MCID) criteria.
Assessing the impact of treatment on health-related 
quality of life in psoriasis
SF-36 summary scores
Using age-, sex-, and race-adjusted data from the 2002
MEPS sample, patients receiving adalimumab were
observed to have significantly greater mean PCS scores at
Week 16 compared with those of the general US popula-
tion (adalimumab mean = 52.7 vs MEPS mean = 48.9; p
< 0.001) (Figure 1). The MCS scores at Week 16 were sim-
ilar between those receiving adalimumab and the general
population (adalimumab mean = 51.2 vs MEPS mean =
50.8; p = 1.000) while patients receiving placebo had
lower scores when compared with the general US popula-
tion (placebo mean = 48.7 vs MEPS mean = 50.8; p <
0.0001) (Figure 2).
Similar findings were observed in comparing PCS and
MCS scores of the REVEAL treatment groups with the gen-
eral population based on the age-, sex-, and race-matched
2002 MEPS data (data not shown). At Week 16, mean PCS
scores for those receiving adalimumab were significantly
greater than mean scores for the general US population
(adalimumab mean = 52.7 vs MEPS mean = 49.3; p <
0.0001) and MCS scores were similar to those for the gen-
eral US population (adalimumab mean = 51.2 vs MEPS
mean = 50.3; p = 0.2440). After 16 weeks, the mean PCS
scores of placebo-treated patients were similar to those for
the general US population (placebo mean = 49.5 vs MEPS
mean = 49.3; p = 0.8052) while the mean MCS scores
were lower than those for the general US population (pla-
cebo mean = 48.7 vs MEPS mean = 50.3; p = 0.0005).
SF-36 scale scores
At Week 16, mean scores for all SF-36 scales had improved
for patients receiving adalimumab therapy and were sim-
ilar to or greater than scores for the NSFHS sample (Table
3). The largest score improvements (baseline to Week 16)
were seen for Bodily Pain and Social Function (+6.8 and
+5.3 points, respectively), while the largest differences in
scores between the adalimumab group and the general US
population were seen for Bodily Pain, Vitality, and Gen-
eral Health (+5.1, +2.8, and +2.5 points, respectively, in
favor of adalimumab). The differences seen in Bodily Pain
are clinically significant (ie, exceeding 3.0 points). For
those receiving placebo, mean scores for all SF-36 scales at
Week 16 were similar to those seen at baseline and were
lower – except for General Health and Vitality – compared
with the NSFHS sample (range -2.3 to +0.9).
Discussion
This study measured the burden of psoriasis on patient
functioning and well-being based on a baseline compari-
son between patients with moderate to severe psoriasis
Mean PCS Scores Across 16 Weeks for REVEAL Trial  Groups Versus General US Population. Figure 1
Mean PCS Scores Across 16 Weeks for REVEAL 
Trial Groups Versus General US Population. General 
US population is the entire MEPS population (N = 23,517). 
SF-12 values from entire MEPS population controlled for age, 
sex, and race. Sample size for adalimumab group at baseline 
and Week 16: n = 805 and n = 755. Sample size for placebo 
group at baseline and Week 16: n = 396 and n = 354. Analy-
sis of covariance with Bonferroni adjustment for multiple 
comparisons. *p < 0.0001
Mean MCS Scores Across 16 Weeks for REVEAL Trial  Groups Versus General US Population Figure 2
Mean MCS Scores Across 16 Weeks for REVEAL 
Trial Groups Versus General US Population. General 
US population is the entire MEPS Population (N = 23,517). 
SF-12 values from entire MEPS population controlled for age, 
sex, and race. Sample size for adalimumab group at baseline 
and Week 16: n = 805 and n = 775. Sample size for placebo 
group at baseline and Week 16: n = 396 and n = 354. Analy-
sis of covariance with Bonferroni adjustment for multiple 
comparisons. *p < 0.001, **p < 0.0001.
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from the REVEAL study and two US general population
samples. Regardless of the data source defining the gen-
eral US population, patients with psoriasis reported simi-
lar physical functioning and more impaired mental health
functioning compared with general population norms,
even after adjusting for age, sex, and race. These findings
differ from those observed based on SF-36 summary
scores in a previous psoriasis clinic sample [5]; however,
the earlier study did not control for differences in age, sex,
or ethnicity in the data analyses.
Based on SF-36 summary scores, there was a significant
mental health burden observed in patients with moderate
to severe psoriasis. The difference in MCS scores between
the REVEAL and the MEPS samples were 3.1 to 3.4 points,
which exceeded the MCID of 3.0 points. This finding is
not surprising given that previous studies have indicated
that patients with psoriasis are more likely to report
depressive symptoms [31,32]. Although the summary
scores for the physical components of health at baseline
were similar between both treatment groups and the gen-
eral US population, SF-36 scale scores indicate that
aspects of physical health such as bodily pain are signifi-
cantly impaired by psoriasis. In a previous study, Rapp et
al. also demonstrated differences in Bodily Pain, Physical
Functioning, and other SF-36 scale scores between a pso-
riasis sample and the NSFHS sample [5].
There were no evident baseline differences in physical
health summary outcomes between REVEAL study groups
and the general US population; however this finding may
not be due to the nature of disease impact on physical
aspects of health, but rather to the method used to derive
PCS scores. PCS scores are based on the positive coeffi-
cients of physical health-related scales (ie, Physical Func-
tion, Bodily Pain, etc.) and negative coefficients of mental
health-related scales (ie, Mental Health, Vitality, etc.). Pre-
vious research has demonstrated that the SF-36 summary
scores may be less informative in situations where there is
impact on both physical and emotional functioning
[33,34]. However, based on the NSFHS data only minor
differences were seen between the REVEAL and general
populations groups on physical functioning and bodily
pain, but there were clinically meaningful differences for
social functioning and role-emotional scores.
We observed significant improvements in MCS and PCS
scores after 16 weeks of adalimumab treatment compared
with US population norms, while the placebo groups dem-
onstrated stability in scores over the treatment course. The
finding that both emotional and physical health were influ-
enced by treatment is consistent with findings observed in
three other psoriasis trials that employed the SF-36
[14,15,18]. Although all three studies demonstrated signif-
icant improvements in all SF-36 scales, the greatest baseline
to endpoint improvements (range of trial durations: 10 to
16 weeks) were seen in the Bodily Pain and Social Function
scales. These findings are also consistent with those
reported for infliximab after 10 weeks of treatment, where
Physical Function, Bodily Pain, General Health, Vitality,
Social Function, and Mental Health scale scores were
greater than or similar to population norms [14].
There were several limitations associated with the norma-
tive comparisons and our analyses. First, the current anal-
ysis was based only on SF-36 normative data in the United
States. However, patients with psoriasis participating in
the REVEAL study were recruited from the United States
and Canada. It is possible that our findings may be
affected by differences in normative scores across different
countries. Second, the health status scores were based on
patient self-reports and may be associated with some bias
in reporting. However, this bias may be minimal given the
strong associations between the clinical endpoints and the
HRQOL measures in this study [14]. Third, the SF-36
summary scores may sometimes yield aberrant results
which are partially explained by the negative weight for
Mental Health and Vitality in scoring the PCS. Finally,
longer term data will be beneficial in confirming the
results of this study.
Table 3: HRQL impact of psoriasis at Week 16: study population versus general US population
Adalimumab Mean (SD)1 Placebo Mean (SD)2 General US Population3 Mean (SD)
Physical Functioning 51.3(9.0) 48.6 (10. 4) 49.4 (10.0)
Role-Physical 52.3(8.4) 49.4 (10.6) 50.1 (9.9)
Bodily Pain 54.3(9.3) 48.9 (10.9) 49.2 (10.2)
General Health 51.8(8.6) 50.2 (9.3) 49.3 (10.7)
Vitality 53.2(9.2) 50.5 (10.4) 50.4 (10.5)
Social Functioning 51.4(8.5) 47.2 (10.9) 50.1 (10.1)
Role-Emotional 51.3(8.9) 48.3 (11.8) 50.6 (9.5)
Mental Health 51.1(9.2) 49.1 (11.0) 49.4 (10.7)
1N = 774–775.
2N = 354.
3SF-36 values for males and females aged 45 to 54 years from SF-36 manual (1998 population); N = 417.Health and Quality of Life Outcomes 2008, 6:75 http://www.hqlo.com/content/6/1/75
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Conclusion
This analysis confirms that psoriasis has a broad impact
on patients' HRQOL. Adalimumab treatment of patients
with psoriasis improved the physical and psychological
health of these patients to levels comparable with or
greater than the physical and psychological health of the
general population in the United States.
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